Trial Profile
A Randomized, Open Label, Comparative Study to Evaluate Effect of Pitavastatin for Reduction of Myocardial Damage in Patient Are Scheduled Elective PCI for Stable Angina Pectoris.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary)
- Indications Angina pectoris
- Focus Pharmacodynamics
- Acronyms PIPA
- Sponsors JW Pharmaceutical
- 29 Mar 2012 Planned end date changed from 1 Aug 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov record.
- 29 Mar 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 09 Dec 2008 Acronym identified as PIPA as reported by ClinicalTrials.gov